HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Miller Fisher Syndrome in the COVID-19 Era - A Novel Target Antigen Calls for Novel Treatment.

Abstract
Although Miller Fisher syndrome cases have been published in this coronavirus disease 2019 (COVID-19) pandemic, anti-GQ1b antibody has not been identified so far. A direct proof of association is not yet available since the exact pathophysiology is not known. Using a proof of contradiction argument, lack of GQ1b serves as the indirect proof that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is probably the infection preceding demyelination. A novel antigen has yet to be described.
AuthorsSurina Kajani, Raheem Kajani, Chin-Wei Huang, Tu Tran, Antonio K Liu
JournalCureus (Cureus) Vol. 13 Issue 1 Pg. e12424 (Jan 01 2021) ISSN: 2168-8184 [Print] United States
PMID33409112 (Publication Type: Case Reports)
CopyrightCopyright © 2021, Kajani et al.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: